KBP Biosciences: Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD

Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage

Related Keywords

United States ,San Antonio ,Texas ,Michigan ,American ,Kostenloser Wertpapierhandel ,James Mccabe ,University Of Chicago Medical Center ,American Heart Association Comprehensive Hypertension Center ,American Heart Association Scientific Sessions ,Renal Associates ,University Of Michigan ,Hepatic Impairment ,Drug Interaction Study Results ,Pablo Pergola ,Mineralocorticoid Receptor Blocker ,Uncontrolled Hypertension ,American Heart Association ,Comprehensive Hypertension Center ,Chicago Medical Center ,Drug Interaction ,Moderate Hepatic ,Deputy Chief Medical ,Julia Yang ,Chief Operations Officer ,Bertram Pitt ,Fred Yang Phd ,Chief Development Officer ,Moderate Hepatic Impairment ,Healthy Subjects ,Kidney Disease ,Clinical Trial ,Biosciences ,Ocedurenone ,8074 ,Featured ,Kidney ,Eek ,Potential ,Treatment ,Option ,Patients ,Uncontrolled ,Resistant ,Hypertension ,Dvanced ,